Bivictrix Therapeutics Limited
Developing The Next Generation of Precision ADCs
BiVictriX Therapeutics Ltd (“BiVictriX”) is a pharmaceutical company focused on developing and licensing novel Antibody Drug Conjugates (“ADCs”), which have been coined as the new ‘Magic Bullet’ therapeutics in the field of oncology. The Company has invented a novel strategy, ‘The Dual Targeting Approach’ that improves ADC selectivity towards cancer cells. The lead and back-up candidate are in the areas of Acute Myeloid Leukaemia (“AML”) and a specific type of Non-Hodgkin Lymphoma. These areas have been targeted due to a combination of unmet clinical need, market size, competition in the field and the specificity of the targeted antigens. The Company is seeking £430k of seed investment to commence operations and grow the Company through the engineering and production of materials to test in pivotal biological assays. Having developed its technology platform over the previous two years, the Company is expected to commence operations in August 2016.